

# Bulletin from the Annual General Meeting of CellaVision AB (publ)

The following resolutions were passed at the Annual General Meeting (the "AGM") of CellaVision AB (publ) ("CellaVision") on 3 May 2024 in Lund.

## Adoption of profit and loss account and balance sheet and discharge from liability

The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet for the financial year 2023. Furthermore, the members of the Board of Directors and the CEO were discharged from liability for the financial year 2023.

## Allocation of profit

The AGM resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2.25 per share with record date on 7 May 2024. The dividend is expected to be paid by Euroclear Sweden AB on 13 May 2024.

## Board of Directors and auditor

The AGM resolved, in accordance with the Nomination committee's proposal, on re-election of Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Louise Armstrong-Denby as Board members. Mikael Worning was also re-elected as the Chairman of the Board of Directors. The AGM resolved on re-election of the audit firm KPMG AB as auditor.

Furthermore, the AGM resolved on remuneration to the Board of Directors, remuneration to the auditor and additional remuneration for work in the Board's committees in accordance with the Nomination committee's proposal.

## Nomination committee for the next Annual General Meeting

The AGM resolved, in accordance with the Nomination committee's proposal, that the principles for appointing the Nomination committee which were adopted at the AGM in 2020 shall apply also for the AGM to be held in 2025.

## Remuneration report

The AGM approved the Board of Directors' remuneration report for the financial year 2023.

## Contact

---

Adele Horn  
Corporate Communications & Investor Relations Manager  
Tel: + 46 46 460 26 04  
[www.cellavision.com](http://www.cellavision.com)  
[adele.horn@cellavision.com](mailto:adele.horn@cellavision.com)

## About Us

---

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at [www.cellavision.com](http://www.cellavision.com)

## Attachments

---

[Bulletin from the Annual General Meeting of CellaVision AB \(publ\)](#)